Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe? Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so Much more to understand across tumor streams ABST0760 #ACR22 https://t.co/z1rhAJZ9gj